BRIO PHARMA
As a Japanese subsidiary of OHSONG PHARM Co., Ltd., we provide integrated solutions to help healthcare products enter the Japanese market.
-
Japan MAH Holder(MAH Type l, ll)
- JMDF ICC
- GQP / GVP
- Consulting
- Regulatory affairs
- Medical Device(Type 2)
-
Japan Medical Device Holder(MAH Type ll)
- GQP / GVP
- Consulting
- Regulatory affairs
BRIO PHARMA PeRFORMANCE (IN JAPAN)
2022, Ibandronate (PFS) approval obtained
2024, Escitalopram (Tablet) approval obtained